Logo do repositório
 
Publicação

Severe cutaneous adverse drug reactions in paediatric age

2025-12Recensão Acesso aberto
Ver registo simples
dc.contributor.authorDourado, Catarina Fidalgo
dc.contributor.authorMoscoso, Teresa Gomes
dc.contributor.authorKong-Cardoso, Bárbara
dc.contributor.institutionEscola Nacional de Saúde Pública (ENSP)
dc.contributor.pblSpringer Nature
dc.date.accessioned2025-12-05T21:16:25Z
dc.date.available2025-12-05T21:16:25Z
dc.date.issued2025-12
dc.descriptionPublisher Copyright: © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2025.
dc.description.abstractPurpose of Review: Severe cutaneous adverse reactions (SCAR) are rare, delayed drug hypersensitivity reactions, that can be potentially life-threatening and are associated with high morbidity. There is limited literature specifically addressing paediatric SCARs, mainly consisting of case reports and small retrospective reviews. This review summarizes current knowledge on the epidemiology, causative drugs, clinical features, differential diagnosis and management of SCARs in children and adolescents. Recent Findings: Recent studies are highlighting the differences between SCARs in adults and children, especially regarding epidemiology, causative drugs, clinical presentation and long-term sequelae. Although the pathophysiology is not completely understood, emerging research suggests possible biomarkers for diagnosis and severity assessment. Considering SCARs management, novel targeted therapies have been studied in adults but are often extrapolated for paediatric use. Summary: SCARs in paediatric age represent a challenge in their recognition, diagnosis and management. Prompt withdrawal of causative drugs, institution of supportive care, early therapeutic initiation and a multidisciplinary approach can lead to better outcomes. Referral to Allergy and Immunology assessment is mandatory to confirm the culprit drug and potential cross-reactivities. Further research addressing specifically paediatric age is needed to establish clinical practice guidelines for children and adolescents.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent1232957
dc.identifier.doi10.1007/s40521-025-00400-4
dc.identifier.issn2196-3053
dc.identifier.otherPURE: 136606797
dc.identifier.otherPURE UUID: 151ef11c-a832-49f7-86a8-a237dcd345f3
dc.identifier.otherScopus: 105017597601
dc.identifier.otherWOS: 001582378100001
dc.identifier.urihttp://hdl.handle.net/10362/191567
dc.identifier.urlhttps://www.scopus.com/pages/publications/105017597601
dc.language.isoeng
dc.peerreviewedyes
dc.subjectAcute generalized exanthematous pustulosis
dc.subjectDrug reaction with eosinophilia and systemic symptoms syndrome
dc.subjectPaediatrics
dc.subjectSevere cutaneous adverse reaction
dc.subjectStevens-Johnson syndrome
dc.subjectToxic epidermal necrolysis
dc.subjectImmunology and Allergy
dc.subjectMedicine (miscellaneous)
dc.subjectSDG 3 - Good Health and Well-being
dc.titleSevere cutaneous adverse drug reactions in paediatric ageen
dc.title.subtitlea narrative reviewen
dc.typereview
degois.publication.issue1
degois.publication.titleCurrent Treatment Options in Allergy
degois.publication.volume12
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Dourado_2025_Current_Treatment_Options_in_Allergy_12_23.pdf
Tamanho:
1.18 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

Home collection (ENSP)